Few studies have investigated the presence of dyslipidaemia in hypertensive individuals. In addition, few data exist on the concurrent treatment of both conditions for the prevention of cardiovascular disease (CVD). This retrospective cohort study examined treatment patterns for hypertension and dyslipidaemia among hypertensive patients in UK primary care. We defined a population of patients aged X40 years from the UK General Practice Research Database. Hypertensive individuals with X3 additional cardiovascular risk factors (ARFs) were compared with a cohort comprising hypertensive patients with p2 ARFs. We analysed the prevalence of risk factors and the prevalence and incidence of treatment for hypertension, dyslipidaemia and for both conditions between January 1997 and December 2001. A total of 117 840 hypertensive patients were identified (23 655 with X3 ARFs, 94 185 with p2 ARFs) in 1997; in 2001, the number diagnosed as hypertensive was 133 683 (40 248 X3 ARFs, 93 435 p2 ARFs). The prevalence of antihypertensive treatment in the hypertensive patients with X3 ARFs increased during the study. In 2001, approximately one-third of hypertensive patients with X3 ARFs were not receiving antihypertensives. Among those patients who received such treatment, the majority received X2 separate agents in accordance with current guidelines. Treatment for concurrent hypertension and dyslipidaemia was initiated in o8% of patients with hypertension and X3 ARFs in each year. These findings demonstrate the under-recognition/undertreatment of cardiovascular risk factors in UK primary care among patients at risk of CVD.
Introduction
In recent years, much research has focused on examining the interplay of cardiovascular risk factors. Hypertension seldom occurs in isolation from other risk factors and is often accompanied by conditions such as glucose intolerance, obesity, left ventricular hypertrophy and dyslipidaemia (including elevated total cholesterol and elevated lowdensity lipoprotein cholesterol). 1 The clustering of multiple cardiovascular risk factors in individuals is common, [1] [2] [3] [4] and it has been observed that the impact of concurrent risk factors on cardiovascular disease (CVD) is more than additive. 5, 6 Dyslipidaemia is found in a high proportion of hypertensive patients, 4, [7] [8] [9] [10] [11] and the presence of both conditions results in a significant increase in the risk of CVD. 12, 13 Recent clinical trials have demonstrated significant benefits of statin therapy on the occurrence and outcome of cardiovascular events in high-risk groups, including patients with a history of coronary heart disease (CHD), patients with type II diabetes and patients aged 70 years or more. [14] [15] [16] [17] The lipid-lowering arm of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) was specifically designed to examine the effects of lipid lowering in hypertensive individuals with multiple cardiovascular risk factors. [18] [19] [20] In hypertensive patients with X3 additional cardiovascular risk factors (ARFs), lipid-lowering therapy conferred a significant reduction in the number of major cardiovascular events even in patients with relatively normal cholesterol levels (total cholesterol p6.5 mmol/l) at baseline. 19 The benefits of prompt and aggressive control of blood pressure (BP) have also been demonstrated in the BP-lowering arm of ASCOT (ASCOT-BPLA) 21 and the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial. 22 In patients at risk of CVD with concurrent hypertension and dyslipidaemia, it is important that both conditions should be treated concomitantly and aggressively. However, little is known about the patterns of treatment of hypertension and dyslipidaemia in the UK primary care setting, particularly in patients at a high risk of CVD.
We, therefore, conducted a study to assess the patterns of antihypertensive and lipid-lowering treatment in hypertensive patients with X3 ARFs and p2 ARFs, using patient-selection criteria based closely on those used in the ASCOT study, 18 to evaluate the extent to which multiple cardiovascular risk factors are recognized and treated.
Materials and methods
This was an observational cohort study using the UK General Practice Research Database (GPRD). 23 
General Practice Research Database
The GPRD is managed by the Medicines and Healthcare products Regulatory Agency (MHRA), the government body responsible for the licensing of medicines and medical devices in the United Kingdom. The validity and completeness of the data contained within the GPRD have been independently established, [24] [25] [26] [27] [28] and the Boston Collaborative Drug Surveillance Program has evaluated and performed quality control of GPRD data since the start of the database. It contains computerized patient records generated directly from participating general practitioners' computers, ensuring that patient prescriptions are accurately recorded in the GPRD. 23 
Study population
The GPRD population enrolled in this study included patients from 114 general practitioner practices that continuously provided up-to-standard patient data from at least 1992-2000. Patients aged X40 years who were present throughout the period 1 January 1996 to 31 December 2001 were used for this study. The year 1996 was used to determine patients' eligibility and the prevalence of risk factors.
Identification of risk factors
The study period was from 1 January 1997 to 31 December 2001. We identified patients who had a history of hypertension on 1 January of each year of the study period. Thus, the population of hypertensive patients increased during the study period. Hypertension was defined as systolic BP X140 mm Hg or diastolic BP X90 mm Hg (based on current European guidelines 29 ), averaged over three successive visits, or pharmacological treatment for hypertension.
The prevalence of hypertension was also assessed by age and gender for patients aged X16 years at the beginning of the study period.
Sensitivity analysis
At the start of the study period, UK guidelines recommended antihypertensive treatment in patients with systolic BP X160 mm Hg or diastolic BP X100 mm Hg. 30 A sensitivity analysis was therefore also undertaken using these thresholds to define hypertension.
Patient cohorts
Hypertensive patients were assigned to either a X3 ARFs or p2 ARFs cohort depending on the presence of ARFs based on the ASCOT study protocol [18] [19] [20] ( Table 1) .
Incidence and prevalence of drug treatment
Rates of treatment with antihypertensive, lipidlowering or concomitant antihypertensive and lipid-lowering drugs were calculated for hypertensive patients with X3 ARFs or p2 ARFs. The annual incidence of treatment was calculated as the number of patients newly treated for the condition in a calendar year among those with the condition and never previously treated. Prevalence of treatment was calculated as the proportion of patients ever treated for a condition among those with the condition on 1 January each year.
An additional analysis, examining the number of hypertensive patients screened for dyslipidaemia in the X3 ARFs or p2 ARFs cohorts for each year of the study period, was also performed.
Numbers of antihypertensive medications used
The current guidelines recommend that hypertensive patients at a high risk of CVD often require two 31 We, therefore, conducted an additional analysis to determine the number of antihypertensive medications being prescribed to patients in the X3 ARFs or p2 ARFs cohorts.
Statistical methods
Time trends in incidence rates were estimated using logistic regression.
Results
Patient demographics in the GPRD at study entry On 1 January 1997, a total of 570 578 patients were recorded in the UK GPRD ( Table 2 ). Of these, 295 170 (51.7%) were men and 275 408 (48.3%) were women. In total, 357 386 (62.6%) of patients were X40 years of age, with 130 277 (22.8%) patients being aged X65 years. The proportion of patients with a recorded diagnosis of hypertension was always slightly higher among men compared with women in the same age group.
Prevalence of risk factors in the study population Among the 357 386 patients aged X40 years in the GPRD in 1997, 117 840 hypertensive patients were identified in whom cardiovascular risk could be accurately assessed. Of these patients, 23 655 (20.1%) had X3 ARFs. The remaining 94 185 patients had p2 ARFs. The most prevalent risk factors in these hypertensive patients were: age X55 years (80.9%), male gender (41.4%), a history of smoking (20.3%) and a history of dyslipidaemia (15.8%) ( Table 3 ).
The proportion of hypertensive patients whose cholesterol concentrations were determined each year was very low, but increased almost threefold between 1997 and 2001, from 7.7 to 21.6% (Table 4) . In 2001, the proportion of patients screened for dyslipidaemia was three times higher in the X3 ARFs cohort than in the p2 ARFs cohort.
Incidence and prevalence of treatment
The incidences of antihypertensive treatment, lipidlowering treatment and concomitant antihypertensive and lipid-lowering treatment were higher in the X3 ARFs cohort than in the p2 ARFs cohort in every year of the study period (Figure 1 ), as were the prevalences of these treatments ( Figure 2 ). The incidence and prevalence of all three treatments increased during the study period. In 2001, 68.3% of patients in the X3 ARFs cohort received antihypertensive drug treatment, 24.2% received lipidlowering drug treatment and 19.9% received concomitant antihypertensive and lipid-lowering treatment. From 1997 to 2001, the incidence of lipid-lowering treatment increased significantly more than the incidence of antihypertensive medication, both in hypertensive patients with X3 ARFs or p2 ARFs ( Table 5 ). The increase in the incidence of concomitant antihypertensive and lipid-lowering treatment was similar to the increase seen with lipid-lowering treatment alone.
Sensitivity analysis
Using the higher thresholds of systolic BP X160 mm Hg or diastolic BP X100 mm Hg, 50 054 hypertensive patients were identified. The prevalence and incidence of antihypertensive treatment were higher with these thresholds than with the lower ones. However, annual rates of increase in incident and prevalent treatment of hypertension between 1998 and 2001 were similar to those observed in the main Table 5 ).
Numbers of antihypertensive medications prescribed
Among the patients who had ever received treatment for hypertension in the GPRD and who were prescribed antihypertensive medication in 2001, 57.8% in the p2 ARFs cohort and 62.0% in the X3 ARFs cohort received combination antihypertensive therapy. Patients who had ever been treated for both hypertension and dyslipidaemia were more likely to receive combination antihypertensive therapy than those treated for hypertension alone (Table 6 ).
Discussion
Hypertension was identified in one-third of all patients aged X40 years in the GPRD during the study period 1997-2001, using thresholds of systolic BP X140 mm Hg or diastolic BP X90 mm Hg. Among hypertensive patients, approximately 20% had three or more ARFs. Both the prevalence and incidence of antihypertensive and lipid-lowering treatment were higher in the X3 ARFs cohort than in the p2 ARFs cohort, indicating that the need for increased therapeutic intervention in patients at a greater risk of CVD was, at least partially, recog- Only 16% of the hypertensive patients in the present study had been diagnosed with concurrent dyslipidaemia in 1997. While the proportion of hypertensive patients with X3 ARFs who were screened for dyslipidaemia increased year-on-year during the study period, approximately 80% of patients with hypertension in 2001 had never had their cholesterol levels measured. Our study was conducted in a UK primary care setting (clinicbased), and at the time of the study, cholesterol screening in the United Kingdom was only recommended in hypertensive individuals with a 10-year coronary risk of 15% or more, or in those patients with diabetes, premature ischaemic heart disease or having a family history of hypercholesterolaemia. 32 As the GPRD only indicates the extent of clinically diagnosed and recorded hypertension and dyslipidaemia among patients who visit their general practitioner, it is likely that the prevalence of dyslipidaemia in hypertensive patients is actually much higher than was observed in our study population. This is confirmed by estimates of the prevalence of dyslipidaemia in hypertensive patients in surveys and studies of electronic medical records which range from approximately 20 to 50%. 3, 4, [7] [8] [9] [10] In the GPRD, we also found a low prevalence of recording for other cardiovascular risk factors. In UK general practice, screening for the presence of diabetes 33 and proteinuria 34 is not routinely performed. Similarly, echocardiographs are only advocated in patients suspected of heart failure. 
Treatment of hypertensive patients with X3 additional risk factors TM MacDonald et al
Lack of routine screening for these risk factors will have contributed to the low prevalence rates of cardiovascular risk factors observed in our study. Moreover, our results imply that cardiovascular risk factors often remain unidentified or unrecorded in UK primary care. Studies have emphasized the need to treat high-risk hypertensive patients with two or more antihypertensive agents. 36 The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High BP now recommends that in patients with BP 420/10 mm Hg above their BP goal, consideration should be given to initiating therapy with two antihypertensive agents; 31 likewise, the Joint British Societies' Guidelines on Prevention of CVD in Clinical Treatment of hypertensive patients with X3 additional risk factors TM MacDonald et al Practice (JBS2) recognize that antihypertensive monotherapy is insufficient in most patients with hypertension and that a combination of BP-lowering agents is needed. 37 In 2001, a large proportion of hypertensive patients, both with X3 ARFs or p2 ARFs, did not receive any antihypertensive medications. However, among the patients who did receive an antihypertensive medication, the majority received two or more different antihypertensive agents, suggesting that the treatment guidelines are being followed to some extent. In contrast, the 1998 Health Survey for England (HSE) found that, among the patients receiving antihypertensive medication, the majority received only one drug (60, 33, 7% received 1, 2, X3 drugs, respectively). 38 This difference, between the HSE and our GPRD results, may be due to a number of factors, particularly recall bias in the HSE, where individuals may have failed to report all of their previous medications when interviewed. Furthermore, the practices in the GPRD may be representative of well-performing practices (all GPRD practices provide up-to-standard research data) and, therefore, may be more likely to adhere to guidelines. A further factor influencing the differences between the HSE and GPRD could be the different years of each study (HSE 1998 , GPRD 2001 . In fact, the recently published report of the 2003 HSE revealed that the number of patients on X2 antihypertensive agents had increased to 56% since 1998. 39 In view of the results of the present study, future guidelines may need to focus on encouraging the initiation and continuation of antihypertensive therapy, to ensure that all hypertensive patients are adequately treated.
Our definitions of CVD-risk factors was based on the criteria used in the ASCOT study. [18] [19] [20] However, three of the cardiovascular risk factors used in ASCOT (electrocardiogram abnormalities; a history of premature CHD in a first-degree relative; plasma total cholesterol/high-density lipoprotein ratio X6) were incompletely recorded in the GPRD, and were not included in our analyses. As a result, some patients with X3 ARFs will have been assigned to the X3 ARFs or p2 ARFs group on the basis of their recorded risk factors.
The lipid-lowering arm of ASCOT examined the effect of a statin on the outcome of clinical events in high-risk hypertensive patients with total cholesterol p6.5 mmol/l at baseline and well-controlled BP throughout the trial. It was found that the occurrence of nonfatal myocardial infarction and fatal CHD was reduced by 36% in the statin group versus placebo. 19 On the basis of these findings, European guidelines now recommend that in high-risk patients without overt CVD, treatment with a statin should be initiated if their total cholesterol is more than 3.5 mmol/l. 29 In 2001, 60.2% of the 5880 hypertensive patients in the GPRD, with known total cholesterol concentrations and who were not treated for dyslipidaemia, were above the threshold of 3.5 mmol/l. In the X3 ARFs cohort, 44.2% had dyslipidaemia. However, only 24.2% of the patients with X3 ARFs were prescribed lipidlowering treatment and only 19.9% were prescribed concomitant antihypertensive and lipid-lowering treatment in 2001. This was a considerable improvement on 1997, when o10% of the high-risk patients were prescribed lipid-lowering treatment or concomitant antihypertensive and lipid-lowering treatment. In light of the current recommendations to treat hypertension and dyslipidaemia concomitantly and aggressively, these results indicate that there remains considerable undertreatment of these conditions.
The GPRD data are limited in that they are observational and clinic-based. Therefore, treatment patterns can only be determined for patients who have sought medical care and where a condition has been diagnosed and recorded by the general 40 However, a review of the literature reports that refill compliance concurs with other measures of adherence, physiological drug effects and serum drug levels. 41 Finally, practices contributing to the GPRD may not be representative of UK primary care overall in terms of motivation and good working practices.
CHD and stroke are the two most common causes of death in the United Kingdom. Although many risk factors for CHD have now been identified, the most powerful predictors of CHD risk are hypertension and abnormal lipid levels. Recent guidelines clearly emphasize the need to evaluate and treat all cardiovascular risk factors. 29, 37, 42, 43 The recent Systematic COronary Risk Evaluation (SCORE) project provides a practical framework for global cardiovascular risk assessment. 42 Risk estimating systems such as SCORE are increasingly important considering the overall failure of medical practice to achieve substantial reductions in cardiovascular risk in Europe. 39, [44] [45] [46] [47] [48] This study demonstrates that dyslipidaemia may often go unrecognized in hypertensive individuals. Moreover, our results indicate a significant gap between treatment guidelines and actual clinical practice. This gap represents a considerable missed opportunity in United Kingdom general practice to improve the prevention of CVD, not only in hypertensive patients at a higher risk of CVD (X3 ARFs), but also in hypertensive individuals at a lower risk (p2 ARFs) of CVD. 
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